You are currently viewing a new version of our website. To view the old version click .
Pharmaceuticals
  • Retraction
  • Open Access

7 February 2025

RETRACTED: Ezz Eldin et al. Design and Synthesis of Novel 5-((3-(Trifluoromethyl)piperidin-1-yl)sulfonyl)indoline-2,3-dione Derivatives as Promising Antiviral Agents: In Vitro, In Silico, and Structure–Activity Relationship Studies. Pharmaceuticals 2023, 16, 1247

,
,
,
,
,
and
1
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Port Said University, Port Said 42526, Egypt
2
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11651, Egypt
3
Department of Science, Prince Sultan Military College of Health Sciences, Dhahran 31932, Saudi Arabia
4
Department of Medical Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo 11651, Egypt
This article belongs to the Section Medicinal Chemistry
The Pharmaceuticals Editorial Office retracts the article “Design and Synthesis of Novel 5-((3-(Trifluoromethyl)piperidin-1-yl)sulfonyl)indoline-2,3-dione Derivatives as Promising Antiviral Agents: In Vitro, In Silico, and Structure–Activity Relationship Studies” [1] cited above.
Following publication, concerns were raised by the publisher regarding the validity of the data published in this article [1].
Adhering to our complaints procedure, an investigation was conducted by the Editorial Office and Editorial Board, which included a review of the raw data presented within this publication. While the authors fully cooperated with the investigation, they were unable to satisfactorily address a number of significant errors and anomalies found in the NMR and IR data. As a result, the Editorial Office and Editorial Board were unable to confirm the reliability of the findings and subsequently decided to retract the paper as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30, accessed on 25 October 2024) and in line with the Committee on Publication Ethics retraction guidelines (https://publicationethics.org/retraction-guidelines, accessed on 25 October 2024).
This retraction was approved by the Editor-in-Chief of the journal Pharmaceuticals.
The authors did not agree to this retraction.

Reference

  1. Ezz Eldin, R.R.; Saleh, M.A.; Alwarsh, S.A.; Rushdi, A.; Althoqapy, A.A.; El Saeed, H.S.; Abo Elmaaty, A. RETRACTED: Design and Synthesis of Novel 5-((3-(Trifluoromethyl)piperidin-1-yl)sulfonyl)indoline-2,3-dione Derivatives as Promising Antiviral Agents: In Vitro, In Silico, and Structure–Activity Relationship Studies. Pharmaceuticals 2023, 16, 1247. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.